TWI810150B - 立即釋放歐西布提寧或其醫藥上可接受之鹽及延遲起始立即釋放毛果芸香鹼或其醫藥上可接受之鹽於製造用於在有其需要的個體中治療多汗症且減少口乾副作用的組成物之用途 - Google Patents

立即釋放歐西布提寧或其醫藥上可接受之鹽及延遲起始立即釋放毛果芸香鹼或其醫藥上可接受之鹽於製造用於在有其需要的個體中治療多汗症且減少口乾副作用的組成物之用途 Download PDF

Info

Publication number
TWI810150B
TWI810150B TW106101040A TW106101040A TWI810150B TW I810150 B TWI810150 B TW I810150B TW 106101040 A TW106101040 A TW 106101040A TW 106101040 A TW106101040 A TW 106101040A TW I810150 B TWI810150 B TW I810150B
Authority
TW
Taiwan
Prior art keywords
pharmaceutically acceptable
acceptable salt
hyperhidrosis
pilocarpine
muscarinic
Prior art date
Application number
TW106101040A
Other languages
English (en)
Chinese (zh)
Other versions
TW201737906A (zh
Inventor
班哲明 麥格羅三世
Original Assignee
美商泰拉維達公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商泰拉維達公司 filed Critical 美商泰拉維達公司
Publication of TW201737906A publication Critical patent/TW201737906A/zh
Application granted granted Critical
Publication of TWI810150B publication Critical patent/TWI810150B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
TW106101040A 2016-01-20 2017-01-12 立即釋放歐西布提寧或其醫藥上可接受之鹽及延遲起始立即釋放毛果芸香鹼或其醫藥上可接受之鹽於製造用於在有其需要的個體中治療多汗症且減少口乾副作用的組成物之用途 TWI810150B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2016/014150 WO2017127073A1 (en) 2016-01-20 2016-01-20 Methods and compositions for treating hyperhidrosis
WOPCT/US16/14150 2016-01-20

Publications (2)

Publication Number Publication Date
TW201737906A TW201737906A (zh) 2017-11-01
TWI810150B true TWI810150B (zh) 2023-08-01

Family

ID=59314209

Family Applications (2)

Application Number Title Priority Date Filing Date
TW106101040A TWI810150B (zh) 2016-01-20 2017-01-12 立即釋放歐西布提寧或其醫藥上可接受之鹽及延遲起始立即釋放毛果芸香鹼或其醫藥上可接受之鹽於製造用於在有其需要的個體中治療多汗症且減少口乾副作用的組成物之用途
TW112107474A TW202341976A (zh) 2016-01-20 2017-01-12 立即釋放歐西布提寧或其醫藥上可接受之鹽及延遲起始立即釋放毛果芸香鹼或其醫藥上可接受之鹽於製造用於在有其需要的個體中治療多汗症且減少口乾副作用的組成物之用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW112107474A TW202341976A (zh) 2016-01-20 2017-01-12 立即釋放歐西布提寧或其醫藥上可接受之鹽及延遲起始立即釋放毛果芸香鹼或其醫藥上可接受之鹽於製造用於在有其需要的個體中治療多汗症且減少口乾副作用的組成物之用途

Country Status (15)

Country Link
US (4) US10328057B2 (cg-RX-API-DMAC7.html)
EP (1) EP3405191B1 (cg-RX-API-DMAC7.html)
JP (1) JP6841834B2 (cg-RX-API-DMAC7.html)
KR (2) KR102600541B1 (cg-RX-API-DMAC7.html)
CN (1) CN108697688A (cg-RX-API-DMAC7.html)
AU (2) AU2016388308B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018014661A2 (cg-RX-API-DMAC7.html)
CA (1) CA3011683C (cg-RX-API-DMAC7.html)
DK (1) DK3405191T3 (cg-RX-API-DMAC7.html)
HK (1) HK1258825A1 (cg-RX-API-DMAC7.html)
MX (1) MX394356B (cg-RX-API-DMAC7.html)
RU (1) RU2718906C2 (cg-RX-API-DMAC7.html)
TW (2) TWI810150B (cg-RX-API-DMAC7.html)
WO (1) WO2017127073A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201805490B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110020423A1 (en) 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
GB2479213B (en) 2010-04-01 2013-07-10 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
EP3405191B1 (en) 2016-01-20 2025-02-19 TheraVida, Inc. Compositions for use in treating hyperhidrosis
US10933020B2 (en) 2018-09-28 2021-03-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
KR20220027943A (ko) 2019-07-05 2022-03-08 스웨디쉬 매치 노스 유럽 에이비 니코틴 함유 입자를 포함하는 충전 재료를 포함하는 경구 파우치형 니코틴 제품
PH12022551038A1 (en) 2019-11-20 2023-05-29 Swedish Match North Europe Ab An oral pouched nicotine product including a filling material comprising nicotine particles
EP3967311A1 (en) * 2020-09-11 2022-03-16 Astellas Pharma Inc. Compounds for use in the treatment of dry mouth
EP4018849B1 (en) 2020-12-22 2024-10-23 Swedish Match North Europe AB A pouched product for oral use
EP4018847B1 (en) 2020-12-22 2024-09-18 Swedish Match North Europe AB A pouched product for oral use
PL4018848T3 (pl) 2020-12-22 2024-11-25 Swedish Match North Europe Ab Wyrób w saszetkach do użytku doustnego zawierający materiał pokrywający przepuszczalny dla cieczy oraz materiał wypełniający
US20240350420A1 (en) * 2021-08-11 2024-10-24 Wayne Stephen ANDREWS Pharmaceutical compositions and methods for treating hyperhidrosis
WO2024162929A1 (en) * 2023-01-27 2024-08-08 Ardi Farma Ilac Pazarlama Ticaret Limited Sirketi A controlled release formulation of propiverine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110244051A1 (en) * 2010-04-01 2011-10-06 Theravida, Inc. Pharmaceutical formulations for the treatment of overactive bladder

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209505A (en) 1979-04-03 1980-06-24 Mikhail Adib R Pilocarpine mouthwash for dry mouth relief
US4302440B1 (en) * 1980-07-31 1986-08-05 Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof
SE450087B (sv) 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
JP4194114B2 (ja) 1994-02-23 2008-12-10 ビーエム リサーチ エイ／エス 制御放出組成物
US5674895A (en) 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
EP0951279A1 (en) 1997-01-10 1999-10-27 Abbott Laboratories Tablet for the controlled release of active agents
JP3608800B2 (ja) * 1997-03-26 2005-01-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗真菌剤およびポリマーでコートされたコアを有するペレット剤
IL136805A0 (en) 1997-12-22 2001-11-25 Euro Celtique Sa A method of preventing abuse of opioid dosage forms
DK1041987T3 (da) 1997-12-22 2006-08-21 Euro Celtique Sa Oral farmaceutisk doseringsform omfattende en kombination af en opioid-agonist og naltrexon
US6482837B1 (en) 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
AU6228799A (en) 1998-10-26 2000-05-15 Tanabe Seiyaku Co., Ltd. Sustained-release particles
FR2795962B1 (fr) 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
WO2001019901A2 (en) 1999-09-14 2001-03-22 Smithkline Beecham Corporation Process for making aqueous coated beadlets
CN100353935C (zh) 1999-11-11 2007-12-12 法马西雅公司 含托特罗定的药物制剂及其应用
WO2001054728A1 (fr) 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha NOUVEAUX REMEDES ET UTILISATION D'UN AGONISTE β3
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003082207A2 (en) 2002-03-29 2003-10-09 Alza Corporation Volume efficient controlled release dosage form
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
WO2004105735A1 (en) 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
EP1651192A1 (en) 2003-08-06 2006-05-03 Nirmal Mulye Pharmaceutical composition containing water soluble drug
JP5610663B2 (ja) 2003-11-04 2014-10-22 スパーナス ファーマシューティカルズ インコーポレイテッド トロスピウムの１日１回剤形
AU2005237360B2 (en) 2004-04-30 2010-10-21 Astellas Pharma Inc. Time-limited release type granular pharmaceutical composition for oral administration and intraoral rapid disintegration tablet containing the composition
US20080254115A1 (en) 2004-05-19 2008-10-16 Rubino Orapin P Micropellet Containing Pellets and Method of Preparing Such Pellets
EP1753405A4 (en) 2004-06-10 2008-09-17 Glatt Air Tech Inc SLOW RELEASE PHARMACEUTICAL PREPARATION
JP2008516893A (ja) 2004-08-27 2008-05-22 スフェリックス，インク． 多層錠剤および生体接着性剤形
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2006132196A1 (ja) 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation β３作動薬を含有する新規な医薬
AU2006284940B2 (en) * 2005-09-02 2012-03-22 Theravida, Inc. Therapy for the treatment of disease
WO2007029087A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Controlled release multiple unit formulations
US20070077300A1 (en) 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
WO2007046102A2 (en) * 2005-10-19 2007-04-26 Menni Menashe Zinger Methods for the treatment of hyperhidrosis
NZ579811A (en) 2007-03-29 2012-02-24 Panacea Biotec Ltd Modified dosage forms of tacrolimus
US7563508B2 (en) 2007-05-30 2009-07-21 Chung Shan Institute Of Science And Technology, Armaments Bureau, M.N.D. Diffusion beads with core-shell structure
WO2009003724A1 (en) 2007-07-03 2009-01-08 Synthon B.V. Tolterodine bead
US8110226B2 (en) 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US9561015B2 (en) * 2007-08-24 2017-02-07 General Electric Company Method and apparatus for voice recording with ultrasound imaging
KR20100059912A (ko) 2007-09-28 2010-06-04 노파르티스 아게 알리스키렌 및 발사르탄의 제약 조합물
JP2011502140A (ja) 2007-10-29 2011-01-20 ルピン・リミテッド トルテロジンの制御放出型医薬組成物
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090247628A1 (en) * 2008-03-25 2009-10-01 Auspex Pharmaceuticals, Inc. Substituted phenylcyclohexylglycolates
JP2013523775A (ja) 2010-04-01 2013-06-17 セラヴィダ，インコーポレイテッド 睡眠の質を改善するための方法
MX348723B (es) 2011-05-10 2017-06-27 Theravida Inc Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
WO2012154770A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
US20140037713A1 (en) * 2012-08-03 2014-02-06 Antares Pharma Ipl, Ag Transdermal compositions for anti-cholinergic agents
JP2015533174A (ja) 2012-10-11 2015-11-19 セラヴィダ，インコーポレイテッド ピロカルピンの医薬製剤
EP3405191B1 (en) 2016-01-20 2025-02-19 TheraVida, Inc. Compositions for use in treating hyperhidrosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110244051A1 (en) * 2010-04-01 2011-10-06 Theravida, Inc. Pharmaceutical formulations for the treatment of overactive bladder

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Anna Campanati,et al. "Oxybutynin for the Treatment of Primary Hyperhidrosis: Current State of the Art", Skin Appendage Disord, 2015; 1, :6–13 *

Also Published As

Publication number Publication date
EP3405191A4 (en) 2019-09-04
HK1258825A1 (zh) 2019-11-22
US10328057B2 (en) 2019-06-25
MX2018008694A (es) 2019-05-15
CN108697688A (zh) 2018-10-23
RU2718906C2 (ru) 2020-04-15
KR20230021184A (ko) 2023-02-13
EP3405191B1 (en) 2025-02-19
KR20180102649A (ko) 2018-09-17
US20220047558A1 (en) 2022-02-17
US20190307727A1 (en) 2019-10-10
JP2019506401A (ja) 2019-03-07
AU2016388308A1 (en) 2018-08-02
US20170202778A1 (en) 2017-07-20
TW202341976A (zh) 2023-11-01
RU2018128047A (ru) 2020-02-20
RU2018128047A3 (cg-RX-API-DMAC7.html) 2020-02-20
MX394356B (es) 2025-03-24
JP6841834B2 (ja) 2021-03-10
US11185533B2 (en) 2021-11-30
ZA201805490B (en) 2019-11-27
US20200188360A1 (en) 2020-06-18
EP3405191A1 (en) 2018-11-28
BR112018014661A2 (pt) 2018-12-11
KR102600541B1 (ko) 2023-11-08
TW201737906A (zh) 2017-11-01
CA3011683A1 (en) 2017-07-27
WO2017127073A1 (en) 2017-07-27
AU2016388308B2 (en) 2022-08-04
AU2022206709A1 (en) 2022-08-11
US11779569B2 (en) 2023-10-10
CA3011683C (en) 2023-09-26
US10610519B2 (en) 2020-04-07
KR102495757B1 (ko) 2023-02-06
DK3405191T3 (da) 2025-05-19

Similar Documents

Publication Publication Date Title
TWI810150B (zh) 立即釋放歐西布提寧或其醫藥上可接受之鹽及延遲起始立即釋放毛果芸香鹼或其醫藥上可接受之鹽於製造用於在有其需要的個體中治療多汗症且減少口乾副作用的組成物之用途
JP2020528075A (ja) 過度の眠気を処置するための方法および組成物
US10182995B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
KR20170068478A (ko) 불면증을 치료하기 위한 조성물 및 방법
US20230165847A1 (en) Methods of use of t-type calcium channel modulators
US9283214B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
US20150313849A1 (en) Methods of Treatment of Attention Deficit Hyperactivity Disorder
US12383506B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
JP2023503056A (ja) ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法
HK1261838A1 (en) Methods and compositions for treating hyperhidrosis
JP2023526634A (ja) 高アンモニア血症を治療するためのオルニチンフェニルアセテートの使用
US20200197316A1 (en) Compositions for Treatment of Attention Deficit Hyperactivity Disorder
US20240350420A1 (en) Pharmaceutical compositions and methods for treating hyperhidrosis
WO1996012481A1 (en) Autism remedy